U.S. financial contributions to the World Health Organization (WHO) have fallen by 25 percent during the coronavirus pandemic, provisional data show, with Washington’s future support to the United Nations agency under review.

The Bill & Melinda Gates Foundation pours investment dollars into disease-fighting efforts, especially for those illnesses that inequitably impact developing nations. The massive non-profit is taking up the cause for a pneumococcal infection with a $90 million investment in Seattle area’s Inventprise. 

The Bill & Melinda Gates Foundation will make a $35 million equity investment in privately owned Exscientia Ltd. to fund the development of antiviral drugs including for the coronavirus, the Oxford-based drug developer said on Sept. 8.

A “revolution” in technology that helped scientists develop Covid-19 vaccines in under a year must be sped up, so that when the next pandemic arrives a shot can be ready in 100 days, an international coalition said on March 10.

Novartis and the Bill & Melinda Gates Foundation have partnered on a single-dose, in vivo gene therapy for sickle cell disease (SCD).

A roundup of biopharma news and updates includes Merck and Eisai’s Keytruda-Lenvima combo hitting the mark in a Phase III study for advanced endometrial cancer.

ViiV Healthcare announced that an independent data safety monitoring board (DSMB) recommended the early unblinding of data from the HIV Prevention Trials Network 084 trial of the investigational, long-acting injectable cabotegravir for HIV prevention in women.

ViiV Healthcare announces investigational injectable cabotegravir is superior to oral standard of care for HIV prevention in women Interim analysis from HPTN 084 study shows long-acting injectable cabotegravir administered every two months is 89% more effective than daily pills in preventing HIV acquisition in women  Findings follow data from HPTN 083, a partner HIV prevention […]

Oxford University will study whether the world’s best-selling prescription medicine adalimumab was an effective treatment for Covid-19 patients in the latest effort to repurpose existing drugs as potential coronavirus therapies.

Johnson & Johnson is in talks with the government of Japan and the Bill and Melinda Gates Foundation about locking up allocations of a potential COVID-19 vaccine in advance of the company producing any of the medicines, the company’s Chief Financial Officer Joseph Wolk told Reuters in an interview.